Skip Navigation


Cerebral Cortex Advance Access originally published online on May 27, 2004
Cerebral Cortex 2004 14(12):1365-1375; doi:10.1093/cercor/bhh097
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
14/12/1365    most recent
bhh097v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Puig, M. V.
Right arrow Articles by Artigas, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Puig, M. V.
Right arrow Articles by Artigas, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2004

Article

In Vivo Excitation of GABA Interneurons in the Medial Prefrontal Cortex through 5-HT3 Receptors

M. Victoria Puig\|[ast ]\|, Noemí Santana\|[ast ]\|, Pau Celada, Guadalupe Mengod and Francesc Artigas

Department of Neurochemistry, Institut d’Investigacions Biomèdiques de Barcelona (CSIC), IDIBAPS, 08036 Barcelona, Spain, \|[ast ]\| The first two authors contributed equally to this study

Serotonin (5-hydroxytryptamine, 5-HT) controls pyramidal cell activity in prefrontal cortex (PFC) through various receptors, in particular, 5-HT1A and 5-HT2A receptors. Here we report that the physiological stimulation of the raphe nuclei excites local, putatively GABAergic neurons in the prelimbic and cingulate areas of the rat PFC in vivo. These excitations had a latency of 36 ± 4 ms and a duration of 69 ± 9 ms and were blocked by the i.v. administration of the 5-HT3 receptor antagonists ondansetron and tropisetron. The latency and duration were shorter than those elicited through 5-HT2A receptors in pyramidal neurons of the same areas. Double in situ hybridization histochemistry showed the presence of GABAergic neurons expressing 5-HT3 receptor mRNA in PFC. These cells were more abundant in the cingulate, prelimbic and infralimbic areas, particularly in superficial layers. The percentages of GAD mRNA-positive neurons expressing 5-HT3 receptor mRNA in prelimbic cortex were 40, 18, 6 and 8% in layers I, II–III, V and VI, respectively, a distribution complementary to that of cells expressing 5-HT2A receptors. Overall, these results support an important role of 5-HT in the control of the excitability of apical dendrites of pyramidal neurons in the medial PFC through the activation of 5-HT3 receptors in GABAergic interneurons.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cereb CortexHome page
N. Santana, G. Mengod, and F. Artigas
Quantitative Analysis of the Expression of Dopamine D1 and D2 Receptors in Pyramidal and GABAergic Neurons of the Rat Prefrontal Cortex
Cereb Cortex, August 9, 2008; (2008) bhn134v1.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. Rusch, B. Musset, H. Wulf, A. Schuster, and D. E. Raines
Subunit-Dependent Modulation of the 5-Hydroxytryptamine Type 3 Receptor Open-Close Equilibrium by n-Alcohols
J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1069 - 1074.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
W. Ji and N. Suga
Serotonergic Modulation of Plasticity of the Auditory Cortex Elicited by Fear Conditioning
J. Neurosci., May 2, 2007; 27(18): 4910 - 4918.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. Stevens, D. Rusch, K. Solt, D. E. Raines, and P. A. Davies
Modulation of Human 5-Hydroxytryptamine Type 3AB Receptors by Volatile Anesthetics and n-Alcohols
J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 338 - 345.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.